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ABSTRACT
Background: Elevated concentrations of serum uric acid are asso-
ciated with increased risk of gout and renal and cardiovascular
diseases. Genetic studies in adults have consistently identified as-
sociations of solute carrier family 2, member 9 (SLC2A9), poly-
morphisms with variation in serum uric acid. However, it is not
known whether the association of serum uric acid with SLC2A9
polymorphisms manifests in children.
Objective: The aim was to investigate whether variation in serum
uric acid is under genetic influence and whether the association with
SLC2A9 polymorphisms generalizes to Hispanic children of the
Viva La Familia Study.
Design: We conducted a genomewide association study with 1.1
million genetic markers in 815 children.
Results: We found serum uric acid to be significantly heritable
[h2 6 SD = 0.45 6 0.08, P = 5.8 3 10211] and associated with
SLC2A9 variants (P values between 10216 and 1027). Several of the
significantly associated polymorphisms were previously identified
in studies in adults. We also found positive genetic correlations
between serum uric acid and BMI z score (rG = 0.45, P = 0.002),
percentage of body fat (rG = 0.28, P = 0.04), fat mass (rG = 0.34,
P = 0.02), waist circumference (rG = 0.42, P = 0.003), and waist-to-
height ratio (rG = 0.46, P = 0.001).
Conclusions: Our results show that variation in serum uric acid in
Hispanic children is under considerable genetic influence and is
associated with obesity-related phenotypes. As in adults, genetic
variation in SLC2A9 is associated with serum uric acid concentra-
tions, an important biomarker of renal and cardiovascular disease
risk, in Hispanic children. Am J Clin Nutr 2015;101:725–32.
Keywords: hyperuricemia, obesity, metabolic syndrome, SNP as-
sociation, urate transporter
INTRODUCTION
Uric acid is the end product of dietary and endogenous purine
metabolism (1). Purines are nitrogen-containing bases that form
the backbone of nucleic acids, DNA, and RNA. Hyperuricemia or
elevated concentrations of serum uric acid (SUA)5 in adults have
been linked to greater risk of metabolic disorders such as hy-
pertension, inflammation, type 2 diabetes, metabolic syndrome,
and renal and cardiovascular disease (CVD) (2–5). Studies in
adults have also shown SUA to be an independent risk factor
for CVD (6, 7). In the past few decades, SUA concentrations,
which are highly affected by lifestyle factors such as diet,
physical activity, and medications, have increased in the
United States (8).
SUA concentrations have been strongly associated with the
metabolic syndrome and its individual components in children
and adolescents from the United States (9, 10) and other countries
(11, 12). SUA in children is dependent on age and puberty stages.
Concentrations of SUA increase from early childhood and sta-
bilize by ;15–17 y of age (13). However, it was also observed
that SUA concentrations are higher in overweight and obese
children and increase at rates on par with normo-uremic and
normal-weight children (14). In adults, hyperuricemia predicts
hypertension (15, 16). Likewise, childhood hyperuricemia is
strongly predictive of adult blood pressure (17). Jones et al. (18)
showed that SUA concentrations in childhood are associated
with adult blood pressure, particularly systolic, and thus may be
an important tool to assess CVD risk in adulthood.
Variation in SUA concentrations is affected by genetic as well
as environmental factors. Population studies have shown that
SUA concentrations are significantly heritable, with heritability
estimates ranging between 15% and 73% (19–22). Genomewide
or candidate gene association studies in these populations have
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shown SUA concentrations to be associated with single nucleotide
variants [single nucleotide polymorphisms (SNPs)] in various uric
acid transporter encoding genes. All of these genetic studies were
conducted in adult populations. Genetic studies in children con-
ducted thus far mainly focused on familial hyperuricemic ne-
phropathy or juvenile gout. Thus, to identify genes and SNPs
associated with variation in SUA concentrations, we conducted
a genomewide association analysis of SUA concentrations in
Hispanic children of the Viva La Familia Study (VFS) (23, 24).
METHODS
Study design and participants
The VFS was designed to investigate genetic and environ-
mental factors affecting obesity and its comorbidities in Hispanic
children. Its enrollment was not limited by country of origin;
however, the majority of families were of Mexican-American
descent. To qualify, families had to have at least 1 obese proband
aged 4–19 y. Thus, the VFS represents a family-based cohort
highly enriched for obesity. A total of 319 Hispanic families
enrolled in the VFS in 2000–2004. The majority of the parents
were either overweight (34%) or obese (57%), and 51% of the
children were classified as obese (.95th BMI percentile) with
BMI z scores ranging from 2.3 to 4.5. Anthropometric and body
composition measurements were conducted in parents and children.
Fasting blood samples were drawn for biochemical profiling of the
children and for genotyping of children and parents. Subjects and
study procedures are described in detail in previous publications
(23, 24). The demographic, genetic, and phenotypic details of the
adult populations used for comparison in this article were previously
published (21, 22, 25, 26).
Ethics
All of the children and their parents gave written informed
consent or assent. The protocol was approved by the Institutional
Review Boards for Human Subject Research of Baylor College of
Medicine and Affiliated Hospitals and the Texas Biomedical
Research Institute. The VFS began in 2001 and is not registered.
Measurement of SUA and other phenotypes
Uric acid was oxidized to allantoin by uricase with the pro-
duction of hydrogen peroxide. The peroxide reacts with 4-
aminoantipyrine and 2,4,6-tribromo-3-hydroxy benzoic acid (Fisher
Diagnostics) in the presence of peroxidase to yield a quinonei-
mine dye. The resulting change in absorbance is proportional to
uric acid concentration in the sample. Methods used to measure
fasting concentrations of biomarkers in blood are described
elsewhere (27, 28). In addition, blood pressure measurements
were taken by using an automated monitor. Anthropometric
measurements were performed by using standardized techniques
according to Lohman et al. (29). Body composition was de-
termined by dual-energy X-ray absorptiometry (30).
Genotyping in Hispanic children
Genotyping of the 815 children for 1.1 million SNPs was
conducted by using marker assays included on the Illumina
HumanOmni1-Quad v1.0 BeadChips (30). Genotype calls were
obtained after scanning on the Illumina BeadStation 500GX and
analyzed by using the GenomeStudio software. Our genotyping
error rate (based on duplicates) was 2 per 100,000 genotypes. The
average call rate per individual sample was 97%. Specific markers
were removed from analysis if they had call rates ,95% (;4000
SNPs) or deviated from Hardy-Weinberg equilibrium at a 5% false-
discovery rate (12 SNPs). SNP genotypes were checked for
Mendelian consistency by using the program SimWalk2 (31). The
estimates of the allele frequencies and their SEs were obtained by
using the software program Sequential Oligogenic Linkage
Analysis Routines (SOLAR version 7.6.2) (32).
Statistical analyses
Quantitative genetic analysis (univariate and bivariate)
A variance components decomposition method was used to es-
timate heritability of SUA and CVD-related phenotypes. This
method is implemented in the software program SOLAR. To es-
timate the genetic contribution to the variation in SUA, its herita-
bility was estimated. Total phenotypic variance can be partitioned
into its genetic and environmental components. The fraction of total
phenotypic variance (s2P) resulting from additive genetic effects




A variance components approach was also used to estimate
phenotypic and genetic correlations between SUA and CVD-
related phenotypes. The approach is described in detail elsewhere
(33). In short, the phenotypic correlation between SUA and other
phenotypes can be explained in terms of its genetic and environ-
mental correlation components. A model in which all of the var-
iables are estimated is compared with a model in which the genetic
correlation is constrained to zero. If the result of this statistical test
is significant, then we infer that the phenotypes share effects of
a common set of genes. For this comparison, the likelihood ratio test
is distributed asymptotically again as a 1/2:1/2 mixture of a chi-
square variable with 1 df and a point mass at zero (34).
Genomewide association analysis using measured genotype
analysis
Association analyses were performed by using the SOLAR
program (version 7.6.2). Each marker genotype was converted to
a covariatemeasure equal to 0, 1, or 2 copies of theminor allele (or,
for missing genotypes, the weighted covariate based on imputa-
tion). These covariates were included in the variance components
mixedmodels for measured genotype analyses (35) vs. null models
that incorporated the random effect of kinship and fixed effects
such as age, sex, their interaction and higher order terms. For the
initial genomewide association screen, we tested each SNP
covariate independently as a 1-df likelihood ratio test. Empirical
thresholds for genomewide significant and suggestive evidence of
association were based on the distribution of P values from 10,000
simulated null genomewide association studies (GWASs; i.e.,
simulations of a heritable trait with no modeled SNP covariate
effects using the VFS pedigree and genotypes). The threshold for
significance (P , 1 3 1027) was defined as the cutoff for the
lower 5% tails of the empirical distribution, and the threshold for
suggestive evidence (P , 1 3 1026) was the minimum P value
obtained not more than once per genome scan. The linkage dis-
equilibrium (LD) was computed in SOLAR by using information
for all genotyped SNPs on all individuals. The effective number
of SNPs given LD was calculated by the method of Moskvina and
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Schmidt (36), as implemented in SOLAR. The average ratio of
the SNP effective number to the actual number obtained from
analysis of 1989 nonoverlapping bins of SNPs was used to cal-
culate the genomewide effective number of tests and thus the
significance threshold for genomewide association. We performed
a quantitative transmission disequilibrium test (implemented in
SOLAR) to test for population stratification (37). An initial ge-
nomewide association screen was conducted on a residual trait
after accounting for the covariates age, sex, their interaction and
higher order terms. Also, to determine the covariates that might
have a significant effect on modulating SUA concentrations, we
tested several CVD risk factors. Of these, BMI z score and sys-
tolic blood pressure were found to be significant covariates for
SUA. Thus, we used age, sex, and their interaction and higher
order terms; BMI z scores; and systolic blood pressure to regress
SUA concentrations and used the residual trait in our GWAS.
RESULTS
SUA concentrations in VFS
The study included data from 815 children participating in the
VFS. The mean (6SD) SUA concentration in participating
children was 5.2 6 1.7 mg/dL. Significant heritability was de-
tected for SUA concentrations [h2 = 0.45 (0.08), P = 5.8 3
10211]. The prevalence of hyperuricemia as classified by SUA
concentrations .2 SDs from the mean was 25%.
SUA concentrations and CVD risk factors
Overall, SUA concentrations were significantly correlated
phenotypically with several CVD risk factors. We partitioned the
phenotypic correlation into genetic and environmental correla-
tions. Significant positive genetic and environmental correlations
were seen between SUA and obesity-related measurements such
as BMI z score, percentage of body fat, and waist circumference.
The genetic correlations indicate the presence of common ge-
netic effects acting on SUA and each of these traits. However, for
other phenotypes (liver function, lipids, systolic blood pressure,
and diabetes-related phenotypes), only environmental correlations
with SUA were significant (Table 1).
Genomewide association analysis
Genomewide association analysis of SUA concentrations
showed strong associations with SNPs in solute carrier protein
TABLE 1
Genetic and phenotypic correlations of serum uric acid with cardiovascular disease risk factors1
Phenotype Mean 6 SD rG (SE) P rE (SE) P rP (SE) P
Serum uric acid, mg/dL 5.22 6 1.7 — — — — — —
Age, y 10.61 6 3.9 — — — — — —
Anthropometric
Birth weight, kg 3.49 6 0.6 20.01 (0.12) 9.5 3 1021 0.21 (1.3) 8.0 3 1021 0.009 (0.03) 8.2 3 1021
BMI z score 1.51 6 1.0 0.45 (0.12) 2.0 3 1023 0.45 (0.07) 3.6 3 1026 0.45 (0.03) 9.6 3 10238
Fat, % 0.33 6 0.09 0.28 (0.12) 3.9 3 1022 0.41 (0.08) 3.0 3 1025 0.35 (0.03) 1.0 3 10223
Fat mass, g 19.28 6 12.2 0.34 (0.12) 1.7 3 1022 0.50 (0.07) 3.7 3 1027 0.43 (0.03) 9.4 3 10236
Waist circumference, cm 76.01 6 18.0 0.42 (0.11) 3.0 3 1023 0.51 (0.07) 7.2 3 1027 0.47 (0.03) 2.0 3 10243
Waist-to-height ratio 0.53 6 0.09 0.46 (0.11) 1.0 3 1023 0.45 (0.08) 1.8 3 1025 0.45 (0.03) 1.1 3 10239
Serum lipids, mg/dL
Triglycerides 105.32 6 56.8 0.17 (0.12) 2.0 3 1021 0.55 (0.08) 2.4 3 1027 0.37 (0.03) 5.8 3 10226
HDL cholesterol 46.83 6 11.1 20.05 (0.11) 6.5 3 1021 20.49 (0.10) 1.5 3 1025 20.25 (0.03) 1.3 3 10212
LDL cholesterol 103.88 6 29.1 20.04 (0.12) 7.1 3 1021 0.21 (0.12) 8.6 3 1022 0.06 (0.03) 7.1 3 1022
Total cholesterol 171.76 6 34.4 0.005 (0.11) 9.7 3 1021 0.26 (0.14) 8.0 3 1022 0.09 (0.03) 9.0 3 1023
Adipokines/inflammatory markers
Leptin, ng/mL 17.96 6 15.0 0.24 (0.13) 9.8 3 1022 0.42 (0.08) 9.2 3 1026 0.34 (0.03) 2.0 3 10223
TNF-a, pg/mL 8.32 6 2.4 0.01 (0.09) 9.2 3 1022 0.02 (0.22) 9.1 3 1021 0.01 (0.03) 7.7 3 1021
ICAM-1, pg/mL 279.92 6 113 20.06 (0.11) 5.9 3 1021 0.35 (0.12) 4.0 3 1023 0.11 (0.03) 3.0 3 1023
IL-6, pg/mL 2.10 6 2.1 0.23 (0.14) 1.1 3 1021 0.12 (0.09) 1.9 3 1021 0.17 (0.03) 7.2 3 1027
MCP-1, pg/mL 312.80 6 90.2 0.22 (0.12) 5.0 3 1022 20.14 (0.12) 2.2 3 1021 0.06 (0.03) 8.1 3 1022
CRP, ng/mL 1188.5 6 1427 0.24 (0.15) 1.2 3 1021 0.28 (0.08) 1.0 3 1023 0.26 (0.03) 5.3 3 10215
Liver function markers, U/L
ALT 24.34 6 24.3 0.08 (0.15) 5.9 3 1021 0.41 (0.08) 9.6 3 1026 0.28 (0.03) 1.2 3 10215
AST 25.11 6 15.1 20.07 (0.13) 5.8 3 1021 0.36 (0.09) 3.0 3 1024 0.15 (0.03) 1.1 3 1025
Diabetes-related phenotypes
Glucose, mg/dL 92.31 6 12.1 0.03 (0.12) 8.2 3 1021 0.17 (0.11) 1.1 3 1021 0.10 (0.03) 5.0 3 1023
Insulin, mU/mL 22.43 6 18.5 0.26 (0.14) 9.2 3 1022 0.45 (0.07) 1.8 3 1026 0.37 (0.03) 7.7 3 10227
C-peptide, ng/mL 2.69 6 1.8 0.002 (0.12) 9.9 3 1021 0.80 (0.14) 2.1 3 1028 0.31 (0.03) 3.6 3 10219
HOMA 5.26 6 4.9 0.23 (0.14) 1.3 3 1021 0.46 (0.07) 1.3 3 1026 0.36 (0.03) 7.2 3 10226
Blood pressure, mm Hg
Systolic 108.13 6 10.9 0.19 (0.14) 1.9 3 1021 0.23 (0.08) 1.0 3 1022 0.21 (0.03) 3.6 3 10210
Diastolic 51.01 6 6.9 20.03 (0.15) 8.5 3 1021 0.04 (0.09) 6.8 3 1021 0.01 (0.03) 7.6 3 1021
1Estimates of the allele frequencies and their SEs were obtained by using the software program Sequential Oligogenic Linkage Analysis Routines
(SOLAR), version 7.6.2 (32). ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; ICAM-1, intercellular adhesion
molecule-1; MCP-1, monocyte chemoattractant protein-1; rE, estimate of environmental correlations; rG, estimate of genetic correlations; rP, estimate of
phenotypic correlations.
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2 family, member 9 (SLC2A9), on chromosome 4 (Figure 1). A
total of 400 SNPs showed an association with SUA concentra-
tions at a genomewide significance level of P , 1 3 1027. All
of the 400 SNPs were in the chromosome 4 region that spanned
;46 kb and covered both SLC2A9 and the adjacent gene WD
repeat-containing protein 1 (WDR1). Genotype distributions of
all significantly associated SNPs conformed to Hardy-Weinberg
equilibrium. Population stratification was not significant as per
the quantitative transmission disequilibrium test and therefore
did not confound our associations. The distribution of P values
from GWASs of SUA showed no evidence of inflation due to
population stratification (Figure 2). The relation pairs (n =
1242) that were used in the analysis are shown in Table 2. The
top 20 significant associations are shown in Table 3. Frequen-
cies of the minor alleles ranged between 0.24 and 0.49, whereas
effect sizes (proportion of the residual phenotypic variance ac-
counted by minor allele of the SNP) ranged between 8.5% and
10% (Table 3). Genotype-specific means of SUA concentrations
showed that minor alleles of most of the SNPs are associated
with lower concentrations of SUA, which is consistent with
adult studies. Details of risk and minor alleles are given in Table
3. To uncover other signals and to offset the overwhelming
FIGURE 1 Genomewide association analysis of serum uric acid in Hispanic children.
FIGURE 2 A Q-Q plot showing the absence of inflation due to population stratification and batch or clustering effects.
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association of SLC2A9 and flanking SNPs, we conducted an-
other GWAS with adjustment for the top 20 significant SNPs
(from the chromosome 4 region) from the previous genomewide
association analysis. Evidence of a suggestive association with
SUA concentrations was found for 2 SNPs: rs12965305 from
docking protein 6 (DOK6) and rs3796879 from glutamyl ami-
nopeptidase (ENPEP). None of the SNPs were associated with
SUA at a significance level of P , 1 3 1027.
Extension of the SLC2A9 association with SUA to children
For several of the significantly associated SNPs (rs6449213,
rs10805346, rs1014290, and rs737267), an association with SUA
was previously reported in Mexican Americans of the San
Antonio Family Heart Study, American Indians of the Strong
Heart Family Study, Western Alaska Natives of the Genetics of
Coronary Artery Disease in Alaska Natives, Zuni Indians of the
Genetics of Kidney Disease in Zuni Indians, and in European
adult populations (Table 4). Interestingly, the effect sizes in
Hispanic children were much higher than those in adults (3–5%)
(38, 39).
DISCUSSION
To our knowledge, this is the first GWAS of SUA concen-
trations in children and the first to extend the strong association of
variants in the SLC2A9 genetic locus with SUA concentrations to
children in a family-based study. GWASs have been conducted
in several adult populations to identify loci associated with SUA
concentrations. Most of these studies showed associations of
SLC2A9 SNPs with SUA concentrations. Vitart et al. (40)
showed the association of SLC2A9 SNPs with SUA concentra-
tions in a Croatian sample and then replicated the result in
a sample from the island of Orkney. Similar associations were
reported in individuals from Germany (41), Sardinia (42), and
the United Kingdom (43). Our group has replicated the associ-
ation of SUA with SLC2A9 SNPs in Mexican American (38),
American Indian (39), Western Alaska Native, and Zuni Indian
adult populations (44, 45). The main aim of all these family-
based studies was to identify genetic determinants of complex
diseases, mainly CVD and chronic kidney disease (21, 22, 25,
44, 45). All of these cohorts, except for Zuni Indians, were
TABLE 2
Relation pairs used in this analysis
Relationships Pairs, n
Identical sibling pair 2
Siblings 888
Half siblings and first cousins 2
Double first cousins 1
Half avuncular 5
First cousins 338
Half first cousins 6
Total 1242
TABLE 3
Significant associations of SLC2A9 SNPs with serum uric acid concentrations1
Genotype-specific means of serum
uric acid concentrations5
SNP Base-pair position2 MGA P value Minor allele/frequency Risk allele3 Effect size,4 % 11 12 22
rs11723388 9804900 3.3 3 10216 A/0.26 G 10 4.21 (2.3) 5.02 (2.1) 5.54 (2.5)
rs11721501 9798233 5.7 3 10216 A/0.26 G 9.9 4.17 (2.3) 5.02 (2.1) 5.55 (2.5)
rs6843466 9537003 1.2 3 10215 A/0.49 G 9.6 4.67 (1.7) 5.32 (1.6) 5.75 (1.9)
rs17251963 9751659 1.3 3 10215 G/0.25 A 9.7 4.12 (1.5) 5.04 (1.6) 5.53 (1.7)
rs13129697 9536065 1.4 3 10215 A/0.49 A 9.6 5.74 (1.9) 5.29 (1.6) 4.66 (1.7)
rs7696983 9604927 1.5 3 10215 A/0.26 G 9.3 4.03 (2.3) 5.06 (1.6) 5.51 (2.5)
rs13113918 9607591 1.5 3 10215 A/0.26 G 9.3 4.03 (2.3) 5.06 (1.6) 5.51 (2.5)
rs7683856 9610045 1.5 3 10215 A/0.26 G 9.3 4.03 (2.3) 5.06 (1.6) 5.51 (2.5)
rs9991278 9611763 1.5 3 10215 A/0.26 G 9.3 4.03 (2.3) 5.06 (2.1) 5.51 (2.5)
rs13111638 9605988 2.1 3 10215 A/0.25 G 9.1 3.97 (1.4) 5.07 (1.6) 5.49 (1.7)
rs4481233 9565177 2.4 3 10215 A/0.24 G 9.0 3.96 (2.3) 5.04 (1.6) 5.51 (1.8)
rs1978274 9854185 2.5 3 10215 C/0.29 A 9.5 4.28 (2.3) 5.06 (2.1) 5.56 (2.5)
rs7669607 9606899 2.4 3 10215 A/0.26 G 8.5 4.03 (2.3) 5.06 (1.6) 5.51 (2.5)
rs9991278 9611817 3.0 3 10215 A/0.26 G 9.1 4.03 (2.3) 5.07 (2.1) 5.51 (2.5)
rs11723439 9560917 3.5 3 10215 A/0.25 G 8.6 3.98 (1.3) 5.08 (1.7) 5.49 (1.7)
rs4697745 9914179 5.1 3 10215 A/0.27 G 9.1 4.24 (1.6) 5.04 (1.6) 5.55 (1.8)
rs7675964 994134 5.7 3 10215 G/0.49 G 9.2 5.73 (1.9) 5.28 (1.6) 4.69 (1.7)
rs938552 9925524 7.0 3 10215 A/0.41 G 8.9 4.53 (1.6) 5.23 (1.7) 5.60 (1.7)
rs6449213 9994215 1.3 3 10214 G/0.25 A 8.6 4.02 (1.4) 5.05 (1.6) 5.50 (1.7)
rs12510549 9885815 2.0 3 10214 G/0.26 A 8.5 4.32 (1.6) 5.04 (1.6) 5.53 (1.8)
1The top 20 associations are shown. Estimates of the allele frequencies and their SEs were obtained by using the software program Sequential Oligogenic
Linkage Analysis Routines (SOLAR), version 7.6.2 (32). The final model included age, age-squared, sex, age 3 sex, age-squared 3 sex, BMI z score, and
systolic blood pressure as covariates. MGA, measured genotype analysis; SLC2A9, solute carrier family 2, member 9; SNP, single nucleotide polymorphism.
2Position based on NCBI Genome Build 36.3.
3Risk allele = allele that is associated with increased serum uric acid concentrations (mg/dL).
4Effect size = proportion of residual phenotypic variance explained by the SNP.
51 = minor allele; 2 = major allele.
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recruited without regard to disease status. Nevertheless, the
obesity rates were still high in these cohorts.
The concentrations of SUA in children are dependent on age,
sex, and puberty stage. Hyperuricemia cutoffs in children are
different from adults and are defined as SUA concentrations .2
SDs above the mean. In this study, ;25% children were hy-
peruricemic with the use of this criterion. The serum uric acid
profile also varied according to age, with older children ($13 y)
having serum uric acid concentrations similar to adults. Hy-
peruricemia is caused by either increased production of uric acid
or decreased renal excretion or a combination of both. In recent
times, children with hyperuricemia increasingly present with
obesity, as is the case in adults. Elevated SUA concentrations in
children and adults are often associated with obesity and the
metabolic syndrome (8, 11, 12, 14, 19, 46, 47). Several in-
vestigators have advocated for uric acid to be a component of
the metabolic syndrome. In a cohort of obese children and ad-
olescents, Denzer et al. (14) found positive correlations between
SUA concentrations and BMI, serum triglycerides, and systolic
blood pressure. They also pointed out that childhood hyperuri-
cemia may be an indicator for pre–metabolic syndrome in obese
youth and an unfavorable cardiovascular profile in obese adults.
In Japanese junior high school students, hyperuricemia was
strongly associated with cardiometabolic risk factors but only in
boys (48). Consistent with other publications, we found positive
correlations of SUA with all components of the metabolic syn-
drome, except for HDL-cholesterol concentrations. Likewise,
SUA concentrations in childhood have been strongly associated
with blood pressure (1, 15, 49–53) and are predictive of adult
hypertension (51). We also found positive correlations of SUA
with systolic and diastolic blood pressure. Soletsky and Feig
(52) showed that uric acid–lowering therapy was effective in
reducing blood pressure and systemic vascular resistance in
obese adolescents. Our GWAS results, when additionally ad-
justed for BMI z score and systolic blood pressure, showed as-
sociations between SUA and SLC2A9 SNPs with stronger effect
sizes. This may be a reflection of the previous reports of a bi-
ological link between blood pressure, adiposity, and SUA, es-
pecially in children (8, 15, 17, 47, 51, 52). Our results of genetic
correlations of SUA with obesity measurements, particularly
waist circumference, are consistent with our results in Mexican-
American adults (21).
The association of SUA concentrations with adiposity and
inflammation is well recognized. Although the mechanism is not
yet clear, obese adults and children have higher SUA concen-
trations as observed in this study and in other studies (14, 53, 54).
Gillum (53) also found independent associations of SUA con-
centrations with systolic blood pressure and waist-to-hip ratio.
Lyngdoh et al. (54) suggested that adiposity might be the link
between hyperuricemia and hypertension. Wasilewska et al. (55)
showed that children with hyperuricemia tend to have higher
concentrations of circulating monocyte chemoattractant protein-
1 and C-reactive protein, which is consistent with our results. In
our study we found strong genetic correlations between SUA and
adiposity measures, suggesting a common set of genes affecting
both of these measures. We did not detect any significant genetic
correlations of SUAwith blood pressure, inflammation markers,
or other cardiometabolic risk factors, although we did find strong
phenotypic correlations between them.
This is the first GWAS of SUA in children. The heritability
estimate for SUA concentrations in this cohort of Hispanic
children was 45%, which is in the same range as reported in adults
TABLE 4
SLC2A9 SNP associations in VFS children that replicate results observed in adults1





Age, y 11.0 6 4.02 47.9 6 14.8 39.5 6 17.0 48.9 6 14.8 36.8 6 13.7 — —
Serum uric acid, mg/dL 5.2 6 1.7 5.4 6 1.4 5.14 6 1.5 5.25 6 1.3 5.9 6 1.7 — —
Hyperuricemia,3 % 25 22 17 14 31 — —
Associated SLC2A9
SNPs,4 P value
rs13129697 9.9 3 10216 — — — 1.8 3 1025 2.3 3 10219 (52)
rs13124563 2.0 3 10212 1.1 3 1025 — — — — —
rs7660895 1.2 3 10214 1.5 3 1024 — — 1.6 3 1026 — —
rs11723439 8.8 3 10215 — — — 3.1 3 1027 — —
rs13111638 3.5 3 10215 — — — 1.5 3 1027 1.1 3 1029 (39)
rs4697701 2.8 3 10215 — — — 1.4 3 1026 — —
rs6832439 3.8 3 10214 6.0 3 1029 7.7 3 10231 2.2 3 1025 8.5 3 1028 — —
rs737267 7.7 3 10214 4.2 3 1028 2.9 3 10229 7.9 3 1026 4.5 3 1027 2.5 3 1029 (38)
rs6449213 2.1 3 10214 1.6 3 1026 1.5 3 10229 1.3 3 1026 4.3 3 1028 6.1 3 10210 (39)
rs10805346 8.4 3 10213 1.8 3 1025 5.4 3 10228 9.5 3 1024 1.2 3 1024 — —
rs1014290 1.0 3 10213 1.9 3 1024 — — 1.6 3 1025 5.6 3 1028 (38)
rs13125029 1.9 3 10210 4.3 3 1025 — — 5.6 3 1027 — —
rs4447863 7.4 3 10213 2.7 3 1022 — — 1.4 3 1026 — —
rs4697695 7.1 3 10214 4.0 3 1022 — — 1.3 3 1024 — —
1GKDZI, Genetics of Kidney Disease in Zuni Indians; GOCADAN, Genetics of Coronary Artery Disease in Alaska Natives; SAFHS, San Antonio
Family Heart Study; SHFS, Strong Heart Family Study; SLC2A9, solute carrier family 2, member 9; VFS, Viva La Familia Study.
2Mean 6 SD (all such values).
3Based on 2 SDs above the serum uric acid means in children and serum uric acid .7 and .6 mg/dL in men and women, respectively.
4SNPs for the VFS, SAFHS, and GKDZI were genotyped as part of genomewide association studies; SNPs for the SHFS and GOCADAN were generated
for candidate gene studies.
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(10, 19–22). The variation in several uric acid transporter genes
have been associated with SUA concentrations in adults (Eu-
ropean and non-European), with variants in SLC2A9 being the
most commonly associated across populations (39–43, 56). In-
terestingly, we replicated the SLC2A9 findings; however, the
associations and effect sizes were stronger in children. One of
the SNPs, rs938552, is in strong LD with a missense poly-
morphism, rs16890979. Because strong genetic correlations
were observed between obesity phenotypes and SUA concen-
trations, we conducted association analysis between them. None
of the SLC2A9 SNPs were associated with obesity phenotypes,
which was in contrast to our results in Mexican-American adults
in whom SLC2A9 SNPs were significantly associated with BMI
and waist circumference (38). In another study, Brandstätter
et al. (57) showed that the association between SLC2A9 and
SUA concentrations was modified by BMI.
We conducted an additional GWAS for SUA, conditioned on
significant SLC2A9 SNPs, to uncover novel signals otherwise
masked by SLC2A9 SNPs. Although we did not find significant
associations between SUA and other genes, we found suggestive
evidence of an association of SUA concentrations with DOK6
and ENPEP. None of these have been previously associated with
SUA concentrations either in adults or in children. However,
they have been shown to be associated with renal function (58)
and blood pressure regulation (59), respectively. In a GWAS in
individuals of African ancestry, urinary albumin-creatinine ratio
was associated with DOK6 (58). DOK6 encodes a member of
a family of intracellular adaptor proteins, expressed highly in
human kidneys, that plays a role in rearranged during trans-
fection signaling cascade (60). ENPEP encodes the glutamyl
aminopeptidase that plays an important role in blood pressure
regulation by facilitating conversion of angiotensin II to an-
giotensin III (59).
The majority of candidate biomarkers that are used in drug
development are usually studied in adults. Given the association
between SUA concentrations and increased risk of gout, hy-
pertension, renal disease, and CVD in adults, and the ability to
predict adult hypertension on the basis of pediatric SUA con-
centrations, the identification of such biomarkers will aid in the
development of new treatment strategies that can be applied early
in life. Although we were able to replicate results from studies in
adults, lack of similar studies in children makes it difficult to
replicate or validate our results. In conclusion, our genomewide
association results of SUA concentrations in children replicate
findings in adults and support SLC2A9 genetic variation as an
important pediatric biomarker of renal disease and CVD risk.
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HHH, Carless MA, Curran JE, Johnson MP, Almasy L, et al. Genome-
wide association analysis confirms and extends the association of
SLC2A9 with serum uric acid levels to Mexican Americans. Front
Genet 2013;4:279.
39. Voruganti VS, Franceschini N, Haack K, Laston S, MacCluer JW,
Umans JG, Comuzzie AG, North KE, Cole SA. Replication of the
effect of SLC2A9 genetic variation on serum uric acid levels in
American Indians. Eur J Hum Genet 2014;22:938–43.
40. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott
SA, Kolcic I, Polasek O, Graessler J, et al. SLC2A9 is a newly iden-
tified urate transporter influencing serum urate concentration, urate
excretion and gout. Nat Genet 2008;40:437–42.
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